Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470895 | 0.82 | DYRK1A (0.48) | TSHRDYRK1ADYRK1BGAALMNA | |
| SCHEMBL4465328 | 0.80 | LMNA (0.46) | TSHRDYRK1ADYRK1BGAALMNA | |
| SCHEMBL4477288 | 0.79 | TSHR (0.47) | TSHRDYRK1ADYRK1BGAALMNA | |
| SCHEMBL4470289 | 0.78 | POLB (0.43) | TSHRDYRK1ADYRK1BGAALMNA | |
| SCHEMBL4483946 | 0.78 | CYP1A2 (0.48) | TSHRDYRK1ADYRK1BLMNAMAPT | |
| SCHEMBL4471715 | 0.73 | SMN1; SMN2 (0.51) | GAAMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL10057754 | 0.68 | NOTUM (0.39) | MAPTPOLBKDM4E | |
| SCHEMBL1925356 | 0.67 | TSHR (0.50) | TSHRGAALMNAMAPTKMT2A | |
| SCHEMBL4476072 | 0.67 | DYRK1A (0.37) | DYRK1ADYRK1BGAAMAPTKMT2A | |
| SCHEMBL182888 | 0.66 | ALDH1A1 (0.57) | GAALMNAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592365-B2 | Substituted pyrroles, compositions containing same, method for making same and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-22 | — | — | US | disclosed |
| EP-1851198-B1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2008-12-31 | — | — | EP | disclosed |
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-10 | — | — | US | disclosed |
| EP-1851198-A1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006084996-A1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | PRMT1, ADPRS, RRM2B | TSHR 2348/4885DYRK1A 1057/4885DYRK1B 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.